Vanguard Group’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-14,692
| Closed | -$39.7K | – | 4641 |
|
|
2023
Q1 | $39.7K | Buy |
+14,692
| New | +$56K | ﹤0.01% | 4490 |
|
|
2022
Q4 | – | Sell |
-5,910
| Closed | -$43K | – | 4581 |
|
|
2022
Q3 | $43K | Sell |
5,910
-375
| -6% | -$4.56K | ﹤0.01% | 4559 |
|
|
2022
Q2 | $78K | Sell |
6,285
-14,196
| -69% | -$133K | ﹤0.01% | 4563 |
|
|
2022
Q1 | $341K | Hold |
20,481
| – | – | ﹤0.01% | 4454 |
|
|
2021
Q4 | $1.33M | Sell |
20,481
-25
| -0.1% | -$1.46K | ﹤0.01% | 4177 |
|
|
2021
Q3 | $1.41M | Buy |
20,506
+229
| +1% | +$16.4K | ﹤0.01% | 4166 |
|
|
2021
Q2 | $1.41M | Buy |
20,277
+11,275
| +125% | +$610K | ﹤0.01% | 4071 |
|
|
2021
Q1 | $591K | Buy |
9,002
+2,118
| +31% | +$161K | ﹤0.01% | 4106 |
|
|
2020
Q4 | $396K | Sell |
6,884
-416
| -6% | -$24.2K | ﹤0.01% | 4000 |
|
|
2020
Q3 | $434K | Sell |
7,300
-1,779
| -20% | -$159K | ﹤0.01% | 3838 |
|
|
2020
Q2 | $1.18M | Sell |
9,079
-24
| -0.3% | -$2.12K | ﹤0.01% | 3570 |
|
|
2020
Q1 | $533K | Hold |
9,103
| – | – | ﹤0.01% | 3659 |
|
|
2019
Q4 | $1.15M | Buy |
9,103
+1,555
| +21% | +$211K | ﹤0.01% | 3605 |
|
|
2019
Q3 | $924K | Sell |
7,548
-525
| -7% | -$106K | ﹤0.01% | 3671 |
|
|
2019
Q2 | $2.41M | Buy |
8,073
+1,347
| +20% | +$562K | ﹤0.01% | 3417 |
|
|
2019
Q1 | $3.03M | Buy |
6,726
+456
| +7% | +$200K | ﹤0.01% | 3323 |
|
|
2018
Q4 | $2.87M | Buy |
6,270
+255
| +4% | +$158K | ﹤0.01% | 3267 |
|
|
2018
Q3 | $5.47M | Hold |
6,015
| – | – | ﹤0.01% | 3199 |
|
|
2018
Q2 | $3.53M | Buy |
6,015
+854
| +17% | +$557K | ﹤0.01% | 3327 |
|
|
2018
Q1 | $3.36M | Buy |
5,161
+3,265
| +172% | +$2.45M | ﹤0.01% | 3289 |
|
|
2017
Q4 | $692K | Buy |
1,896
+537
| +40% | +$205K | ﹤0.01% | 3686 |
|
|
2017
Q3 | $416K | Buy |
1,359
+608
| +81% | +$231K | ﹤0.01% | 3786 |
|
|
2017
Q2 | $359K | Buy |
751
+210
| +39% | +$159K | ﹤0.01% | 3786 |
|
|
2017
Q1 | $674K | Buy |
541
+142
| +36% | +$68.3K | ﹤0.01% | 3684 |
|
|
2016
Q4 | $161K | Buy |
399
+3
| +0.8% | +$1.2K | ﹤0.01% | 3922 |
|
|
2016
Q3 | $166K | Sell |
396
-21
| -5% | -$9.39K | ﹤0.01% | 3929 |
|
|
2016
Q2 | $195K | Hold |
417
| – | – | ﹤0.01% | 3955 |
|
|
2016
Q1 | $216K | Sell |
417
-3
| -0.7% | -$1.68K | ﹤0.01% | 3943 |
|
|
2015
Q4 | $329K | Buy |
420
+7
| +2% | +$6.88K | ﹤0.01% | 3917 |
|
|
2015
Q3 | $566K | Hold |
413
| – | – | ﹤0.01% | 3811 |
|
|
2015
Q2 | $828K | Buy |
+413
| New | +$1.05M | ﹤0.01% | 3716 |
|
Vanguard Group's HTGM Position: Q2 2023 in Review
Vanguard Group sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 14,692 shares — an estimated $39.7K sold.
Vanguard Group first reported a position in HTGM in Q2 2015 and held it in 31 quarters. The position peaked at $5.47M in Q3 2018. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- Vanguard Group reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Vanguard Group sold 14,692 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $39.7K.
- Vanguard Group first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 31 quarters.
- Vanguard Group's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $5.47M in Q3 2018.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on Vanguard Group's 13F filing for Q2 2023, filed 14 Aug 2023.